SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.19 CNY | +2.68% |
|
+1.43% | -21.65% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Companyâs main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The Company distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
9.19
CNY
Average target price
6.4
CNY
Spread / Average Target
-30.36%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.65% | 1.67B | |
| +20.44% | 21.89B | |
| +8.46% | 14.45B | |
| +13.07% | 13.63B | |
| +37.46% | 11.49B | |
| -8.59% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.35% | 5.06B | |
| -5.36% | 4.66B |
- Stock Market
- Equities
- 002399 Stock
- News Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
- Shenzhen Hepalink Pharmaceutical Projects Higher H1 Profit
